Unknown

Dataset Information

0

Risk of recurrent stroke and antiplatelet choice in breakthrough stroke while on aspirin.


ABSTRACT: Uncertainty regarding an optimal antiplatelet regimen still exists in patients with breakthrough acute ischemic stroke (AIS) while on aspirin. This study provides an analysis of a prospective multicenter registry between April 2008 and April 2014. Eligible patients were on aspirin at the time of AIS and treated with antiplatelet regimens (aspirin, clopidogrel, or clopidogrel-aspirin). Potential factors associated with the choice of each antiplatelet regimen were explored and included a predictive risk score for future vascular events, the Essen Stroke Risk Score (ESRS). A total of 2348 patients (age, 69 ± 11 years; male, 57.7%) were analyzed, and 55.3%, 25.3% and 19.4% were treated with clopidogrel-aspirin, aspirin and clopidogrel, respectively. While the likelihood of choosing clopidogrel-aspirin increased as the ESRS increased, the likelihood of choosing aspirin decreased as the ESRS increased (Ptrend < 0.001). The ESRS category (0-1/2-3/ ≥ 4) modified the effect of antiplatelet regimens for 1-year vascular events (Pinteraction < 0.01). Among patients with ESRS ≥ 4, clopidogrel-aspirin (HR 0.47 [0.30-0.74]) and clopidogrel (HR 0.30 [0.15-0.60]) significantly reduced the risk of outcome events. Our study showed that more than half of the patients with aspirin failure were treated with clopidogrel-aspirin. In particular, a higher ESRS, which indicates an increased risk of recurrent stroke, was associated with the choice of clopidogrel-aspirin rather than aspirin.

SUBMITTER: Kim JT 

PROVIDER: S-EPMC7541489 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications


Uncertainty regarding an optimal antiplatelet regimen still exists in patients with breakthrough acute ischemic stroke (AIS) while on aspirin. This study provides an analysis of a prospective multicenter registry between April 2008 and April 2014. Eligible patients were on aspirin at the time of AIS and treated with antiplatelet regimens (aspirin, clopidogrel, or clopidogrel-aspirin). Potential factors associated with the choice of each antiplatelet regimen were explored and included a predictiv  ...[more]

Similar Datasets

| S-EPMC2714259 | biostudies-literature
| S-EPMC5829906 | biostudies-literature
| S-EPMC6251602 | biostudies-literature
| S-EPMC3033359 | biostudies-literature
| S-EPMC3086673 | biostudies-literature
| S-EPMC4256539 | biostudies-literature
| S-EPMC6193486 | biostudies-literature
| S-EPMC3250274 | biostudies-literature
| S-EPMC5739731 | biostudies-literature